3-bromo-5-[1,3]dioxolan-2-yl-phenol | 909854-23-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-bromo-5-[1,3]dioxolan-2-yl-phenol
• 英文别名: 3-bromo-5-(1,3-dioxolan-2-yl)phenol
• CAS: 909854-23-5
• 化学式: C₉H₉BrO₃
• 分子量: 245.073
• InChiKey: ACZCYMBZIVORET-UHFFFAOYSA-N

物化性质

• 沸点：
  345.2±42.0 °C(Predicted)
• 密度：
  1.638±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-bromo-5-[1,3]dioxolan-2-yl-phenol 在 硫酸 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 0.08h， 以3.89 g的产率得到3-溴-5-羟基苯甲醛
  参考文献：
  名称：

  Covalent Assembly of Molecular Ladders

  摘要：

  [n]-Rung molecular ladders (n = 3-6) have been prepared by reacting discrete, complimentary m-phenylene ethynylene oligomers using imine formation/exchange. The nanostructures, which in the largest case measure approximately 1.6 x 6.2 nm, have been characterized by MALDI mass spectrometry and gel permeation chromatography. Although the ladder structure is a significant component in each case, the formation of higher molecular weight byproducts becomes more pronounced as the length increases. These structures represent an important first step toward the synthesis of larger, more sophisticated two-dimensional molecular grids.

  DOI：

  10.1021/ja0690013
• 作为产物：
  描述：

  间硝基苯甲醛 在 platinum on activated charcoal N-溴代丁二酰亚胺(NBS) 、 甲酸 、 对甲苯磺酸 、 三乙胺 、 sodium nitrite 作用下， 以 硫酸 、 水 、 溶剂黄146 、 苯 为溶剂， 反应 3.17h， 生成 3-bromo-5-[1,3]dioxolan-2-yl-phenol
  参考文献：
  名称：

  Covalent Assembly of Molecular Ladders

  摘要：

  [n]-Rung molecular ladders (n = 3-6) have been prepared by reacting discrete, complimentary m-phenylene ethynylene oligomers using imine formation/exchange. The nanostructures, which in the largest case measure approximately 1.6 x 6.2 nm, have been characterized by MALDI mass spectrometry and gel permeation chromatography. Although the ladder structure is a significant component in each case, the formation of higher molecular weight byproducts becomes more pronounced as the length increases. These structures represent an important first step toward the synthesis of larger, more sophisticated two-dimensional molecular grids.

  DOI：

  10.1021/ja0690013

文献信息

• Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
  申请人：Binggeli Alfred

  公开号：US20060205718A1

  公开（公告）日：2006-09-14

  This invention is concerned with compounds of the formula wherein A, B 1 , B 2 , R 1 , R 2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A、B 1 、B 2 、R 1 、R 2 和G如描述和索赔中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1858901A1

  公开（公告）日：2007-11-28
• US7645753B2
  申请人：——

  公开号：US7645753B2

  公开（公告）日：2010-01-12
• [EN] BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS<br/>[FR] DERIVES DE BENZOTHIAZOLE, DE THIAZOLOPYRIDINE, DE BENZOOXAZOLE ET D'OXAZOLOPYRIDINE EN TANT QUE COMPOSES ANTIDIABETIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2006094682A1

  公开（公告）日：2006-09-14

  [EN] This invention is concerned with compounds of the formula (I) wherein A, B¹, B², R¹, R² and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
  [FR] L'invention concerne des composés de formule (I), où A, B¹, B², R¹, R² et G sont tels que définis dans la description et dans les revendications, ainsi que leurs sels pharmaceutiquement acceptables. L'invention concerne également des compositions pharmaceutiques contenant de tels composés, leur procédé de fabrication, ainsi que leur utilisation pour le traitement et/ou la prévention de maladies associées à la modulation de récepteurs SST de sous-type 5.